{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:35:47Z","timestamp":1760621747017},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CDS"],"published-print":{"date-parts":[[2006,5,1]]},"DOI":"10.2174\/157488606776930544","type":"journal-article","created":{"date-parts":[[2008,5,12]],"date-time":"2008-05-12T20:53:51Z","timestamp":1210625631000},"page":"169-178","source":"Crossref","is-referenced-by-count":13,"title":["The Role of the New Zealand Intensive Medicines Monitoring Programme in Identification of Previously Unrecognised Signals of Adverse Drug Reactions"],"prefix":"10.2174","volume":"1","author":[{"given":"David","family":"Clark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mira","family":"Harrison-Woolrych","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/55810","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T09:24:18Z","timestamp":1448270658000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/openurl\/content.php?genre=article&issn=1574-8863&volume=1&issue=2&spage=169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,1]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,5,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/157488606776930544","relation":{},"ISSN":["1574-8863"],"issn-type":[{"value":"1574-8863","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5,1]]}}}